IQVIA Holdings Inc. (IQV) |
| 178.81 8.17 (4.79%) 02-27 16:00 |
| Open: | 168.47 |
| High: | 179.23 |
| Low: | 167.125 |
| Volume: | 5,206,393 |
| Market Cap: | 30,451(M) |
| PE Ratio: | 22.81 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 244.16 |
| Resistance 1: | 210.74 |
| Pivot price: | 172.33 |
| Support 1: | 156.67 |
| Support 2: | 130.35 |
| 52w High: | 247.05 |
| 52w Low: | 134.65 |
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
| EPS | 7.830 |
| Book Value | 38.340 |
| PEG Ratio | 0.00 |
| Gross Profit | 32.017 |
| Profit Margin (%) | 8.34 |
| Operating Margin (%) | 15.17 |
| Return on Assets (ttm) | 5.1 |
| Return on Equity (ttm) | 21.4 |
Sat, 28 Feb 2026
IQVIA HOLDINGS INC. ($IQV) CEO 2025 Pay Revealed - Quiver Quantitative
Sat, 28 Feb 2026
Keystone Investors PTE Ltd. Has $27.78 Million Holdings in IQVIA Holdings Inc. $IQV - MarketBeat
Sat, 28 Feb 2026
Erste Asset Management GmbH Trims Stock Position in IQVIA Holdings Inc. $IQV - MarketBeat
Sat, 28 Feb 2026
IQVIA Holdings: Still Exceeding Expectations As A Stealth Compounder (NYSE:IQV) - Seeking Alpha
Fri, 27 Feb 2026
IQVIA Releases its 2025 Sustainability Report - Business Wire
Thu, 26 Feb 2026
Is IQVIA Holdings Inc. (IQV) a Buy Post Earnings? - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |